Efg Asset Management (North America) Corp. Halozyme Therapeutics, Inc. Transaction History

Efg Asset Management (North America) Corp.

$724 Million
Q3 2025

A detailed history of Efg Asset Management (North America) Corp. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 79,436 shares of HALO stock, worth $5.56 Million. This represents 0.8% of its overall portfolio holdings.

Number of Shares

79,436

Previous 104,439 23.94%

Holding current value

$5.56 Million

Previous $5.43 Million 7.23%

% of portfolio

0.8%

Previous 0.81%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 03, 2025	SELL	$52.92 - $78.28 $1.32 Million - $1.96 Million	-25,003 Reduced 23.94%	79,436 $5.83 Million
Q2 2025 Aug 05, 2025	BUY	$47.91 - $70.14 $64,534 - $94,478	1,347 Added 1.31%	104,439 $5.43 Million
Q1 2025 May 14, 2025	SELL	$47.74 - $65.16 $1.2 Million - $1.64 Million	-25,202 Reduced 19.64%	103,092 $6.58 Million
Q4 2024 Feb 11, 2025	BUY	$42.57 - $61.09 $846,334 - $1.21 Million	19,881 Added 18.34%	128,294 $6.13 Million
Q3 2024 Nov 12, 2024	SELL	$51.3 - $64.42 $1.63 Million - $2.05 Million	-31,856 Reduced 22.71%	108,413 $6.2 Million

Q2 2024 Jul 25, 2024	BUY	$37.81 - $52.4 $6,805 - $9,432	180 Added 0.13%	140,269 $7.34 Million
Q1 2024 May 13, 2024	BUY	$33.68 - $41.95 $315,143 - $392,526	9,357 Added 7.16%	140,089 $5.7 Million
Q4 2023 Feb 08, 2024	SELL	$33.32 - $42.1 $233,473 - $294,994	-7,007 Reduced 5.09%	130,732 $4.83 Million
Q3 2023 Nov 02, 2023	SELL	$36.46 - $44.03 $140,079 - $169,163	-3,842 Reduced 2.71%	137,739 $5.26 Million
Q2 2023 Jul 28, 2023	BUY	$30.28 - $38.74 $790,641 - $1.01 Million	26,111 Added 22.61%	141,581 $5.11 Million
Q1 2023 Apr 27, 2023	SELL	$32.86 - $55.7 $299,091 - $506,981	-9,102 Reduced 7.31%	115,470 $4.41 Million
Q4 2022 Feb 03, 2023	SELL	$40.06 - $59.44 $1.05 Million - $1.56 Million	-26,183 Reduced 17.37%	124,572 $7.09 Million
Q3 2022 Oct 28, 2022	SELL	$38.53 - $51.78 $817,375 - $1.1 Million	-21,214 Reduced 12.34%	150,755 $5.96 Million
Q2 2022 Aug 04, 2022	SELL	$37.35 - $48.3 $4.57 Million - $5.91 Million	-122,444 Reduced 41.59%	171,969 $7.57 Million
Q1 2022 Apr 26, 2022	SELL	$31.97 - $41.06 $39,738 - $51,037	-1,243 Reduced 0.42%	294,413 $11.7 Million
Q4 2021 Feb 18, 2022	BUY	$31.82 - $40.75 $9.41 Million - $12 Million	295,656 New	295,656 $11.9 Million

Others Institutions Holding HALO

# of Institutions

667

Shares Held

128M

Call Options Held

626K

Put Options Held

455K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $9.75B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.

Account

Efg Asset Management (North America) Corp. Halozyme Therapeutics, Inc. Transaction History